| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
|
Gagelmann, Nico
|
|
|
|
10 |
p. e786-e795
|
artikel
|
| 2 |
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
|
Yan, Zhiling
|
|
2019
|
|
10 |
p. e521-e529
|
artikel
|
| 3 |
Acute leukodystrophy: elevated risk for neurocognitive impairment and imaging abnormalities
|
Armstrong, F Daniel
|
|
2016
|
|
10 |
p. e447-e448
nvt p.
|
artikel
|
| 4 |
Adaptive cancer treatment: why I put my money on immunotherapy
|
Porrata, Luis F
|
|
2015
|
|
10 |
p. e402-e403
nvt p.
|
artikel
|
| 5 |
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
|
Voorhees, Peter M
|
|
|
|
10 |
p. e825-e837
|
artikel
|
| 6 |
Aging and transplanting graciously
|
de Lima, Marcos
|
|
2015
|
|
10 |
p. e398-e399
nvt p.
|
artikel
|
| 7 |
A glimmer of hope for older people with acute myeloid leukaemia
|
Bermúdez, Arancha
|
|
|
|
10 |
p. e700-e701
|
artikel
|
| 8 |
Allogeneic haematopoietic stem-cell transplantation versus gene therapy for haemoglobinopathies
|
Olson, Timothy S
|
|
|
|
10 |
p. e798-e800
|
artikel
|
| 9 |
All-trans retinoic acid for treating immune thrombocytopenia: new purpose for an old drug?
|
Gabarin, Nadia
|
|
|
|
10 |
p. e672-e673
|
artikel
|
| 10 |
All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial
|
Huang, Qiu-Sha
|
|
|
|
10 |
p. e688-e699
|
artikel
|
| 11 |
An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes
|
Pleyer, Lisa
|
|
|
|
10 |
p. e714-e716
|
artikel
|
| 12 |
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
|
Redjoul, Rabah
|
|
|
|
10 |
p. e681-e683
|
artikel
|
| 13 |
An unmet need for long-term follow-up in Hodgkin's lymphoma?
|
Gisselbrecht, Christian
|
|
2018
|
|
10 |
p. e435-e436
|
artikel
|
| 14 |
Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study
|
Gadalla, Shahinaz M
|
|
|
|
10 |
p. e715-e723
|
artikel
|
| 15 |
A survey on the patient perspective on cure in multiple myeloma
|
Mohyuddin, Ghulam Rehman
|
|
|
|
10 |
p. e716-e719
|
artikel
|
| 16 |
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
|
Bazinet, Alexandre
|
|
|
|
10 |
p. e756-e765
|
artikel
|
| 17 |
Beta-thalassaemia: all roads lead to a cure?
|
The Lancet Haematology,
|
|
2018
|
|
10 |
p. e430
|
artikel
|
| 18 |
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation
|
Sureda, Anna
|
|
|
|
10 |
p. e790-e791
|
artikel
|
| 19 |
Blood transfusion strategies in elderly patients
|
Murphy, Michael F
|
|
2017
|
|
10 |
p. e453-e454
nvt p.
|
artikel
|
| 20 |
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
|
Monagle, Paul
|
|
2019
|
|
10 |
p. e500-e509
|
artikel
|
| 21 |
Brentuximab vedotin for lymphoma in paediatric patients
|
Sureda, Anna
|
|
2018
|
|
10 |
p. e433-e434
|
artikel
|
| 22 |
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
|
Locatelli, Franco
|
|
2018
|
|
10 |
p. e450-e461
|
artikel
|
| 23 |
Caregivers—an undervalued and underused essential
|
The Lancet Haematology,
|
|
|
|
10 |
p. e707
|
artikel
|
| 24 |
CAR T cells in CNS-relapsed leukaemia: one step forward
|
Rives, Susanna
|
|
|
|
10 |
p. e675-e676
|
artikel
|
| 25 |
CD19 CAR T cells for infants and young children
|
Shalabi, Haneen
|
|
|
|
10 |
p. e712-e714
|
artikel
|
| 26 |
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials
|
Leahy, Allison Barz
|
|
|
|
10 |
p. e711-e722
|
artikel
|
| 27 |
Changing landscape of anticoagulation therapy in children
|
Sharathkumar, Anjali A
|
|
2019
|
|
10 |
p. e490-e491
|
artikel
|
| 28 |
Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 Demographic and Health Survey
|
Nnodu, Obiageli E
|
|
|
|
10 |
p. e723-e731
|
artikel
|
| 29 |
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|
Passamonti, Francesco
|
|
|
|
10 |
p. e737-e745
|
artikel
|
| 30 |
Communicating sickle cell disease point-of-care testing results
|
Jaja, Cheedy
|
|
|
|
10 |
p. e708-e709
|
artikel
|
| 31 |
Correction to Lancet Haematol 2015; 2: e315
|
|
|
2015
|
|
10 |
p. e407-
1 p.
|
artikel
|
| 32 |
Correction to Lancet Haematol 2020; 7: e370–80
|
|
|
|
|
10 |
p. e710
|
artikel
|
| 33 |
Correction to Lancet Haematol 2023; 10: e713–34
|
|
|
|
|
10 |
p. e796
|
artikel
|
| 34 |
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3
|
|
|
|
|
10 |
p. e796
|
artikel
|
| 35 |
COVID-19 and haematological malignancy: navigating a narrow strait
|
Rubinstein, Samuel M
|
|
|
|
10 |
p. e701-e703
|
artikel
|
| 36 |
Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma
|
Popat, Rakesh
|
|
|
|
10 |
p. e788-e789
|
artikel
|
| 37 |
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
|
DiNardo, Courtney D
|
|
|
|
10 |
p. e724-e736
|
artikel
|
| 38 |
Direct oral anti-Xa inhibitors and vaginal bleeding
|
Ferreira, Melanie
|
|
2016
|
|
10 |
p. e451-e452
nvt p.
|
artikel
|
| 39 |
Effects of the COVID-19 pandemic on supply and use of blood for transfusion
|
Stanworth, Simon J
|
|
|
|
10 |
p. e756-e764
|
artikel
|
| 40 |
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
|
Dimopoulos, Meletios Athanasios
|
|
|
|
10 |
p. e801-e812
|
artikel
|
| 41 |
Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism
|
Buckstein, Rena
|
|
2015
|
|
10 |
p. e396-e397
nvt p.
|
artikel
|
| 42 |
Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change
|
Mohyuddin, Ghulam Rehman
|
|
|
|
10 |
p. e704-e706
|
artikel
|
| 43 |
Erythropoietin on cycling performance
|
Bejder, Jacob
|
|
2017
|
|
10 |
p. e459-e460
nvt p.
|
artikel
|
| 44 |
Erythropoietin on cycling performance
|
Kappelle, Laurens J W
|
|
2017
|
|
10 |
p. e461-e462
nvt p.
|
artikel
|
| 45 |
Erythropoietin on cycling performance
|
Sperlich, Billy
|
|
2017
|
|
10 |
p. e462-
1 p.
|
artikel
|
| 46 |
Erythropoietin on cycling performance
|
Fagundes, Nelson J R
|
|
2017
|
|
10 |
p. e459-
1 p.
|
artikel
|
| 47 |
Erythropoietin on cycling performance
|
van Breda, Eric
|
|
2017
|
|
10 |
p. e460-
1 p.
|
artikel
|
| 48 |
Erythropoietin on cycling performance
|
Lundby, Carsten
|
|
2017
|
|
10 |
p. e460-e461
nvt p.
|
artikel
|
| 49 |
Erythropoietin on cycling performance – Authors' reply
|
Heuberger, Jules A A C
|
|
2017
|
|
10 |
p. e462-e464
nvt p.
|
artikel
|
| 50 |
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis
|
Schünemann, Holger J
|
|
|
|
10 |
p. e746-e755
|
artikel
|
| 51 |
Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice
|
Malard, Florent
|
|
|
|
10 |
p. e776-e785
|
artikel
|
| 52 |
Filling a gap in UK health services: the role of charities
|
The Lancet Haematology,
|
|
|
|
10 |
p. e697
|
artikel
|
| 53 |
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study
|
Huntington, Scott F
|
|
2015
|
|
10 |
p. e408-e416
nvt p.
|
artikel
|
| 54 |
Frosted branch angiitis after allogeneic haematopoietic stem cell transplantation in adult T-cell leukaemia-lymphoma
|
Kamoi, Koju
|
|
|
|
10 |
p. e772
|
artikel
|
| 55 |
Gene therapy for sickle cell disease
|
The Lancet Haematology,
|
|
2016
|
|
10 |
p. e446-
1 p.
|
artikel
|
| 56 |
Global burden of sickle cell disease in 2021
|
Brousse, Valentine
|
|
|
|
10 |
p. e792
|
artikel
|
| 57 |
Global burden of sickle cell disease in 2021 – Authors' reply
|
Kassebaum, Nicholas J
|
|
|
|
10 |
p. e792-e793
|
artikel
|
| 58 |
Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study
|
Uyoga, Sophie
|
|
2015
|
|
10 |
p. e437-e444
nvt p.
|
artikel
|
| 59 |
G6PD deficiency: a polymorphism balanced by heterozygote advantage against malaria
|
Luzzatto, Lucio
|
|
2015
|
|
10 |
p. e400-e401
nvt p.
|
artikel
|
| 60 |
Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care
|
Okello, Clement D
|
|
|
|
10 |
p. e756-e769
|
artikel
|
| 61 |
Haematology in sub-Saharan Africa: advances and opportunities in health care, education, and research
|
Makani, Julie
|
|
|
|
10 |
p. e678-e681
|
artikel
|
| 62 |
Haematology's role on the path to health for all Africans
|
The Lancet Haematology,
|
|
|
|
10 |
p. e671
|
artikel
|
| 63 |
Heparins as cancer therapy: in theory, they should have worked
|
Posch, Florian
|
|
|
|
10 |
p. e703-e704
|
artikel
|
| 64 |
High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis
|
Mithoowani, Siraj
|
|
2016
|
|
10 |
p. e489-e496
nvt p.
|
artikel
|
| 65 |
High-dose dexamethasone or oral prednisone for immune thrombocytopenia?
|
Godeau, Bertrand
|
|
2016
|
|
10 |
p. e453-e454
nvt p.
|
artikel
|
| 66 |
High-risk interim PET negative patients in Hodgkin's lymphoma
|
Meignan, Michel
|
|
2016
|
|
10 |
p. e449-e450
nvt p.
|
artikel
|
| 67 |
IFNL4 and donor selection for matched unrelated donor haematopoietic stem-cell transplantation
|
Westervelt, Peter
|
|
|
|
10 |
p. e698-e699
|
artikel
|
| 68 |
Immunoglobulin therapy and passive transfer of anti-HBc: too often forgotten
|
Hui, Edwin Pun
|
|
2018
|
|
10 |
p. e437-e438
|
artikel
|
| 69 |
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials
|
von Tresckow, Bastian
|
|
2018
|
|
10 |
p. e462-e473
|
artikel
|
| 70 |
INWORKS study: risk of leukaemia from protracted radiation exposure
|
Doss, Mohan
|
|
2015
|
|
10 |
p. e404-e405
nvt p.
|
artikel
|
| 71 |
INWORKS study: risk of leukaemia from protracted radiation exposure
|
Nagataki, Shigenobu
|
|
2015
|
|
10 |
p. e404-
1 p.
|
artikel
|
| 72 |
INWORKS study: risk of leukaemia from protracted radiation exposure – Authors' reply
|
Schubauer-Berigan, Mary K
|
|
2015
|
|
10 |
p. e405-e406
nvt p.
|
artikel
|
| 73 |
Iron deficiency anaemia in sub-Saharan Africa: a review of current evidence and primary care recommendations for high-risk groups
|
Mwangi, Martin N
|
|
|
|
10 |
p. e732-e743
|
artikel
|
| 74 |
Ironing out frequent blood donation
|
Devine, Dana V
|
|
2019
|
|
10 |
p. e492-e493
|
artikel
|
| 75 |
Is oral all-trans retinoic acid plus danazol a refinement of second-line therapy for primary immune thrombocytopenia in adults?
|
Panzer, Simon
|
|
2017
|
|
10 |
p. e457-e458
nvt p.
|
artikel
|
| 76 |
Japan's high-cost medical expense benefit system could be an obstacle to promoting generic imatinib
|
Ureshino, Hiroshi
|
|
2019
|
|
10 |
p. e498
|
artikel
|
| 77 |
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
|
Fink, Anna Maria
|
|
2017
|
|
10 |
p. e475-e486
nvt p.
|
artikel
|
| 78 |
Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach?
|
Rossi, Davide
|
|
2017
|
|
10 |
p. e455-e456
nvt p.
|
artikel
|
| 79 |
Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis
|
Cheung, Yin Ting
|
|
2016
|
|
10 |
p. e456-e466
nvt p.
|
artikel
|
| 80 |
Living with sickle cell disease: voices from sub-Saharan Africa
|
Salim, Arafa Said
|
|
|
|
10 |
p. e684-e685
|
artikel
|
| 81 |
Longer-term efficiency and safety of increasing the frequency of whole blood donation (INTERVAL): extension study of a randomised trial of 20 757 blood donors
|
Kaptoge, Stephen
|
|
2019
|
|
10 |
p. e510-e520
|
artikel
|
| 82 |
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
|
Taher, Ali T
|
|
|
|
10 |
p. e733-e744
|
artikel
|
| 83 |
Luspatercept in patients with non-transfusion dependent β-thalassaemia
|
Platzbecker, Uwe
|
|
|
|
10 |
p. e709-e711
|
artikel
|
| 84 |
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series
|
Beyer-Westendorf, Jan
|
|
2016
|
|
10 |
p. e480-e488
nvt p.
|
artikel
|
| 85 |
Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures
|
Smit, Yolba
|
|
|
|
10 |
p. e849-e859
|
artikel
|
| 86 |
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
|
Michels, Naomi
|
|
|
|
10 |
p. e700-e710
|
artikel
|
| 87 |
Mitapivat for treatment of pyruvate kinase deficiency
|
Costa, Fernando F
|
|
|
|
10 |
p. e708-e709
|
artikel
|
| 88 |
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial
|
Glenthøj, Andreas
|
|
|
|
10 |
p. e724-e732
|
artikel
|
| 89 |
Mixing blood and politics
|
Ranscombe, Peter
|
|
2019
|
|
10 |
p. e499
|
artikel
|
| 90 |
Modelling the mortality of sickle cell disease in Africa
|
Wonkam, Ambroise
|
|
|
|
10 |
p. e677-e678
|
artikel
|
| 91 |
Monika Asnani — addressing the unmet needs of sickle cell disease
|
Cavanaugh, Ray
|
|
|
|
10 |
p. e721
|
artikel
|
| 92 |
Multitargeted CAR T-cell therapy in multiple myeloma
|
Susanibar Adaniya, Sandra
|
|
2019
|
|
10 |
p. e494-e495
|
artikel
|
| 93 |
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
|
Cramer, Paula
|
|
|
|
10 |
p. e745-e755
|
artikel
|
| 94 |
Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial
|
Feng, Fei-Er
|
|
2017
|
|
10 |
p. e487-e496
nvt p.
|
artikel
|
| 95 |
Orla McCourt—making space for proactive rehabilitation in haematology
|
Siva, Nayanah
|
|
|
|
10 |
p. e797
|
artikel
|
| 96 |
Outcomes of restrictive versus liberal transfusion strategies in older adults from nine randomised controlled trials: a systematic review and meta-analysis
|
Simon, Geoff I
|
|
2017
|
|
10 |
p. e465-e474
nvt p.
|
artikel
|
| 97 |
Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review
|
Lu, Huifang
|
|
2018
|
|
10 |
p. e474-e478
|
artikel
|
| 98 |
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
|
Versluis, Jurjen
|
|
2015
|
|
10 |
p. e427-e436
nvt p.
|
artikel
|
| 99 |
Putting precursor haematological conditions centre stage
|
The Lancet Haematology,
|
|
|
|
10 |
p. e785
|
artikel
|
| 100 |
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
|
Keane, Colm
|
|
2015
|
|
10 |
p. e445-e455
nvt p.
|
artikel
|
| 101 |
Regulatory hurdles for CAR T-cell therapy in Japan
|
Nagai, Sumimasa
|
|
|
|
10 |
p. e686-e687
|
artikel
|
| 102 |
Revisiting six established practices in the treatment of chronic myeloid leukaemia
|
Kantarjian, Hagop M
|
|
|
|
10 |
p. e860-e864
|
artikel
|
| 103 |
Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study
|
Søgaard, Kirstine Kobberøe
|
|
2018
|
|
10 |
p. e441-e449
|
artikel
|
| 104 |
Risk stratification for Down syndrome and acute lymphocytic leukaemia: one size does not fit all
|
Rabin, Karen R
|
|
|
|
10 |
p. e673-e675
|
artikel
|
| 105 |
Routine haematological parameters in COVID-19 prognosis
|
Pereyra, David
|
|
|
|
10 |
p. e709
|
artikel
|
| 106 |
Safe blood supply in sub-Saharan Africa: challenges and opportunities
|
Dei-Adomakoh, Yvonne
|
|
|
|
10 |
p. e770-e776
|
artikel
|
| 107 |
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
|
Platzbecker, Uwe
|
|
2015
|
|
10 |
p. e417-e426
nvt p.
|
artikel
|
| 108 |
Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study
|
Trab, Trine
|
|
|
|
10 |
p. e838-e848
|
artikel
|
| 109 |
Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact
|
Smith, Stephen D
|
|
|
|
10 |
p. e707
|
artikel
|
| 110 |
Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact – Authors' reply
|
Kalakonda, Nagesh
|
|
|
|
10 |
p. e707-e708
|
artikel
|
| 111 |
Should patients with haemophilia receive gene therapy?
|
VandenDriessche, Thierry
|
|
|
|
10 |
p. e722-e723
|
artikel
|
| 112 |
Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care
|
Esoh, Kevin
|
|
|
|
10 |
p. e744-e755
|
artikel
|
| 113 |
Sickle cell disease strategies and priorities
|
Luzzatto, Lucio
|
|
|
|
10 |
p. e794-e795
|
artikel
|
| 114 |
Sickle cell disease strategies and priorities
|
Bonnechère, Bruno
|
|
|
|
10 |
p. e793-e794
|
artikel
|
| 115 |
Sickle cell disease strategies and priorities – Authors' reply
|
Piel, Frédéric B
|
|
|
|
10 |
p. e795
|
artikel
|
| 116 |
Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
|
Rodriguez-Otero, Paula
|
|
|
|
10 |
p. e786-e787
|
artikel
|
| 117 |
Splanchnic vein thrombosis: what are the long-term risks?
|
Schulman, Sam
|
|
2018
|
|
10 |
p. e431-e432
|
artikel
|
| 118 |
Staunching the rising costs of haematological health care
|
Ruiz-Argüelles, Guillermo J
|
|
2016
|
|
10 |
p. e455-
1 p.
|
artikel
|
| 119 |
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
|
Dimopoulos, Meletios A
|
|
|
|
10 |
p. e813-e824
|
artikel
|
| 120 |
Tackling adherence in sickle cell disease with mHealth
|
Hankins, Jane S
|
|
|
|
10 |
p. e713-e714
|
artikel
|
| 121 |
Tail events with cancer treatment
|
Hilal, Talal
|
|
|
|
10 |
p. e712
|
artikel
|
| 122 |
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
|
van de Donk, Niels WCJ
|
|
2018
|
|
10 |
p. e479-e492
|
artikel
|
| 123 |
Thalidomide for myeloma: still here?
|
Dimopoulos, Meletios A
|
|
2018
|
|
10 |
p. e439-e440
|
artikel
|
| 124 |
The big business of blood plasma
|
The Lancet Haematology,
|
|
2017
|
|
10 |
p. e452-
1 p.
|
artikel
|
| 125 |
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study
|
Agostinelli, Claudio
|
|
2016
|
|
10 |
p. e467-e479
nvt p.
|
artikel
|
| 126 |
The evolving multi-agent options for chronic lymphocytic leukaemia treatment
|
de la Serna, Javier
|
|
|
|
10 |
p. e711-e712
|
artikel
|
| 127 |
The overlooked COST of multiple myeloma
|
de Souza, Jonas A
|
|
2015
|
|
10 |
p. e394-e395
nvt p.
|
artikel
|
| 128 |
The peripheral T-cell lymphomas: an unusual path to cure
|
Ma, Helen
|
|
|
|
10 |
p. e765-e771
|
artikel
|
| 129 |
The underrepresented majority
|
León, Andrés Gómez-De
|
|
|
|
10 |
p. e720
|
artikel
|
| 130 |
Thromboembolism: an under appreciated cause of death
|
The Lancet Haematology,
|
|
2015
|
|
10 |
p. e393-
1 p.
|
artikel
|
| 131 |
46th virtual annual meeting of the EBMT
|
del Pozo Martín, Yaiza
|
|
|
|
10 |
p. e711
|
artikel
|
| 132 |
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study
|
Ghorashian, Sara
|
|
|
|
10 |
p. e766-e775
|
artikel
|
| 133 |
Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia
|
Soumerai, Jacob D
|
|
|
|
10 |
p. e796
|
artikel
|
| 134 |
Venous thromboembolism prophylaxis strategies for patients undergoing elective total knee replacement
|
Kozieł, Monika
|
|
2019
|
|
10 |
p. e496-e497
|
artikel
|
| 135 |
Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis
|
Lewis, Sedina
|
|
2019
|
|
10 |
p. e530-e539
|
artikel
|
| 136 |
World Thrombosis Day—5 years on
|
The Lancet Haematology,
|
|
2019
|
|
10 |
p. e489
|
artikel
|
Tijdschrift beschrijving